180 related articles for article (PubMed ID: 28629699)
1. Understanding the applicability of results from primary care trials: lessons learned from applying PRECIS-2.
Forbes G; Loudon K; Treweek S; Taylor SJC; Eldridge S
J Clin Epidemiol; 2017 Oct; 90():119-126. PubMed ID: 28629699
[TBL] [Abstract][Full Text] [Related]
2. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
[TBL] [Abstract][Full Text] [Related]
3. Improving the relevance of randomised trials to primary care: a qualitative study investigating views towards pragmatic trials and the PRECIS-2 tool.
Forbes G; Loudon K; Clinch M; Taylor SJC; Treweek S; Eldridge S
Trials; 2019 Dec; 20(1):711. PubMed ID: 31829266
[TBL] [Abstract][Full Text] [Related]
4. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
Trials; 2016 Jan; 17():32. PubMed ID: 26772801
[TBL] [Abstract][Full Text] [Related]
5. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
[TBL] [Abstract][Full Text] [Related]
6. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
[TBL] [Abstract][Full Text] [Related]
7. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
[TBL] [Abstract][Full Text] [Related]
8. The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.
Dal-Ré R
Eur J Clin Pharmacol; 2021 Apr; 77(4):539-546. PubMed ID: 33106910
[TBL] [Abstract][Full Text] [Related]
9. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research.
Gaglio B; Phillips SM; Heurtin-Roberts S; Sanchez MA; Glasgow RE
Implement Sci; 2014 Aug; 9():96. PubMed ID: 25163664
[TBL] [Abstract][Full Text] [Related]
10. [The PRECIS-2 tool: designing trials that are fit for purpose].
Hu GP; Zhan SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):222-226. PubMed ID: 29495210
[TBL] [Abstract][Full Text] [Related]
11. PRECIS-2 for retrospective assessment of RCTs in systematic reviews.
Zwarenstein M; Thorpe K; Treweek S; Loudon K
J Clin Epidemiol; 2020 Oct; 126():202-206. PubMed ID: 32565215
[TBL] [Abstract][Full Text] [Related]
12. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
Thorpe KE; Zwarenstein M; Oxman AD; Treweek S; Furberg CD; Altman DG; Tunis S; Bergel E; Harvey I; Magid DJ; Chalkidou K
J Clin Epidemiol; 2009 May; 62(5):464-75. PubMed ID: 19348971
[TBL] [Abstract][Full Text] [Related]
13. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
Sharma T; Qamar I; Zwarenstein M
J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
[TBL] [Abstract][Full Text] [Related]
14. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.
Loudon K; Zwarenstein M; Sullivan F; Donnan P; Treweek S
Trials; 2013 Apr; 14():115. PubMed ID: 23782862
[TBL] [Abstract][Full Text] [Related]
15. Designing pragmatic trials-what can we learn from lessons learned?
Groenwold RHH; Dekkers OM
J Clin Epidemiol; 2017 Oct; 90():3-5. PubMed ID: 28629700
[TBL] [Abstract][Full Text] [Related]
16. The Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) instrument was useful for refining a randomized trial design: experiences from an investigative team.
Riddle DL; Johnson RE; Jensen MP; Keefe FJ; Kroenke K; Bair MJ; Ang DC
J Clin Epidemiol; 2010 Nov; 63(11):1271-5. PubMed ID: 20670911
[TBL] [Abstract][Full Text] [Related]
17. Pragmatic vs. explanatory: an adaptation of the PRECIS tool helps to judge the applicability of systematic reviews for daily practice.
Koppenaal T; Linmans J; Knottnerus JA; Spigt M
J Clin Epidemiol; 2011 Oct; 64(10):1095-101. PubMed ID: 21474282
[TBL] [Abstract][Full Text] [Related]
18. The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
Bratton DJ; Nunn AJ; Wojnarowska F; Kirtschig G; Sandell A; Williams HC
Trials; 2012 Apr; 13():50. PubMed ID: 22540678
[TBL] [Abstract][Full Text] [Related]
19. Are trials of psychological and psychosocial interventions for schizophrenia and psychosis included in the NICE guidelines pragmatic? A systematic review.
Gastaldon C; Mosler F; Toner S; Tedeschi F; Bird VJ; Barbui C; Priebe S
PLoS One; 2019; 14(9):e0222891. PubMed ID: 31550279
[TBL] [Abstract][Full Text] [Related]
20. Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool.
Dal-Ré R
Eur J Clin Pharmacol; 2020 Aug; 76(8):1093-1102. PubMed ID: 32447436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
